As many as 40% of cancer patients receiving immune checkpoint inhibitors experience immune-related adverse events.

HealthDay News — COVID-19 is associated with long-term risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Nov. 6 in JAMA Dermatology.

Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.

Various types of topical therapies are effective for the treatment of periorbital dyschromia, including caffeine, growth factors, and more.